Cargando…
Macrophage activation syndrome in a patient with adult-onset Still’s disease following first COVID-19 vaccination with BNT162b2
BACKGROUND: Adult-onset Still’s disease (AOSD) is an autoinflammatory multi-systemic syndrome. Macrophage activation syndrome (MAS) is a potentially life-threatening complication of AOSD with a mortality rate of 10–20%. Especially viral infection is thought to be a common trigger for development of...
Autores principales: | Muench, Frédéric, Krusche, Martin, Sander, Leif Erik, Rose, Thomas, Burmester, Gerd-Rüdiger, Schneider, Udo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712099/ https://www.ncbi.nlm.nih.gov/pubmed/34961551 http://dx.doi.org/10.1186/s41927-021-00237-9 |
Ejemplares similares
-
Adult-onset Still’s Disease after BNT162b2 mRNA COVID-19 Vaccine
por: Park, Seong Yeon, et al.
Publicado: (2021) -
Rare, rarer, lung involvement in adult-onset Still's disease: A mini-review
por: Nies, Jasper F., et al.
Publicado: (2022) -
Interleukin-1/6 Blockade for the Treatment of Severe Steroid-Refractory BNT162b2 Vaccine-Induced Adult-Onset Still’s Disease
por: Hugues, Benjamin, et al.
Publicado: (2022) -
Thiamazol-induzierte Arthritis
por: Brinkman, Antonia, et al.
Publicado: (2020) -
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)